| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.019 | 0.7 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0059 | 0.9 |